[HTML][HTML] Pembrolizumab for the treatment of non–small-cell lung cancer

EB Garon, NA Rizvi, R Hui, N Leighl… - … England Journal of …, 2015 - Mass Medical Soc
Background We assessed the efficacy and safety of programmed cell death 1 (PD-1)
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …

[HTML][HTML] Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study

EB Garon, MD Hellmann, NA Rizvi… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …

[HTML][HTML] Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE …

TC Mitchell, O Hamid, DC Smith, TM Bauer… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Tumors may evade immunosurveillance through upregulation of the indoleamine 2,
3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly selective IDO1 enzyme …

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

NB Leighl, MD Hellmann, R Hui… - The Lancet …, 2019 - thelancet.com
Background The anti-programmed death 1 monoclonal antibody pembrolizumab has shown
antitumour activity and is a first-line and second-line treatment option for patients with …

[HTML][HTML] Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

TC Gangadhar, O Hamid, DC Smith, TM Bauer… - … for immunotherapy of …, 2015 - Springer
Background Indoleamine 2, 3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme
that is expressed in many cancers and induces immune tolerance by suppressing T cell …

Safety and clinical activity of MEDI1873, a novel GITR agonist, in advanced solid tumors

AS Balmanoukian, JR Infante, R Aljumaily, A Naing… - Clinical Cancer …, 2020 - AACR
Purpose: The safety and preliminary efficacy of MEDI1873, an agonistic IgG1 fusion protein
targeting glucocorticoid-induced TNF receptor–related protein (GITR), were evaluated in an …

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study

ER Ahn, M Rothe, PK Mangat, E Garrett-Mayer… - JCO Precision …, 2023 - ascopubs.org
PURPOSE The TAPUR Study is a pragmatic basket trial evaluating antitumor activity of
commercially available targeted agents in patients with advanced cancers harboring …

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization …

AK Ganti, M Rothe, PK Mangat… - JCO Precision …, 2023 - ascopubs.org
PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket
trial evaluating antitumor activity of commercially available targeted agents in patients with …

[HTML][HTML] Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring …

M Nagasaka, AS Balmanoukian, R Madison, SS Zhang… - Lung Cancer, 2022 - Elsevier
The sequential use of 1 st-/2 nd-generation to 3 rd-generation epidermal growth factor
(EGFR) tyrosine kinase inhibitors (TKIs) has led to the emergence of triple EGFR mutations …

P2. 39: long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab: track: immunotherapy

S Ramalingam, R Hui, L Gandhi, E Carcereny… - Journal of Thoracic …, 2016 - jto.org
Background The anti–PD-1 antibody pembrolizumab (MK-3475) received accelerated
approval in the United States for the treatment of PD-L1–expressing NSCLC that progressed …